Methods to sense and treat subclinical skin damage
OwnerRobert K. Ilowiteinventor
Life of this patent
Estimating the term…
Abstract
A method of sensing and removing subclinical, precancerous cells from skin wherein the unblemished skin is not being treated for AK, fine lines or clinical wrinkles and is not chronically exposed to sun or UV radiations, the method comprising topically applying to skin of a patient a composition essentially comprising of an TLR7 agonist agent, Imiquimod in an amount effective to induce a cellular immune response in the skin resulting in the sensing and removal of subclinical, atypical keratinocytes by erythema, scaling, crusting, or combinations thereof.
Claims20
A method of sensing and removing subclinical precancerous cells from unblemished skin without any clinical evidence of skin damage wherein the unblemished skin is not chronically exposed to sun or UV radiations, the method comprising:
- topically applying to skin of a patient a composition essentially comprising an immunomodulator in an amount effective to induce erythema, scaling, crusting, or combinations thereof.
A method of inducing a favorable immune cell response in skin having subclinical skin damage, no previous actinic keratoses, and no previous nonmelanoma skin cancer, and where the skin is not being treated for fine lines or clinical wrinkles, the method comprising:
- topically administering to the skin an effective amount of a composition comprising an immune cell response agent during a cycle of therapy that is in the range of two to four weeks;
- and
- observing the skin for the response;
- wherein the composition is administered once or twice daily during the cycle of therapy, which is repeated at least once on a substantially annual basis.
A method of early diagnosis of actinic keratosis comprising activating the immune response against subclinical cell damage destined to develop actinic keratosis, the method comprising:
- topically administering to the skin of the patient a composition essentially comprising Imiquimod.
A method of preventing actinic keratosis comprising topically administering to unblemished skin, not being treated for AK, fine lines or clinical wrinkles, an amount of an immune cell response agent effective to induce death of sub-clinically damaged cells in the unblemished skin, wherein death of the sub-clinically damaged cells is visible as erythema, scaling and/or crusting.
Dependencies are inferred from the claim text.